Table 1.
Enrolment demographic and clinical characteristics of participants at-risk for reinfection
| Variables | Overall N=120 |
HCV Reinfection N=10 |
No reinfection a N=110 |
|---|---|---|---|
| Age at enrolment, median (IQR) | 36 (29–46) | 44 (36–49) | 35 (24–46) |
| Gender | |||
| Male | 100 (83) | 10 (100) | 90 (82) |
| Female | 19 (16) | 0 | 19 (17) |
| Transgender | 1 (1) | 0 | 1 (1) |
| Full or part-time employment | 68 (56) | 5 (50) | 63 (57) |
| Tertiary education or greater, n (%) | 70 (58) | 8 (80) | 62 (56) |
| Social functioning score, median (IQR) | 11 (6–16) | 16 (12–17) | 11 (6–15) |
| HIV infection, n (%) | 64 (53) | 7 (70) | 57 (52) |
| On cART, n (%) | 52 (81) | 5 (71) | 47 (82) |
| IDU, n (%) | |||
| Ever prior to enrolment | 83 (69) | 7 (70) | 77 (69) |
| Previous 6 months prior to enrolment | 59 (49) | 6 (60) | 53 (48) |
| Previous 30 days prior to enrolment | 52 (43) | 6 (60) | 46 (42) |
| Age at first IDU, median (IQR) | 25 (20–34) | 35 (30–46) | 25 (20–32) |
| OST, n (%) | |||
| Ever prior to enrolment | 14 (12) | 1 (10) | 13 (13) |
| At enrolment | 6 (5) | 1 (10) | 5 (5) |
| Mode of primary HCV acquisition, n (%) | |||
| IDU | 66 (55) | 6 (60) | 60 (55) |
| Sexual exposure | 51 (43) | 4 (40) | 47 (43) |
| Other | 3 (3) | 0 | 3 (3) |
| Weeks between estimated date of HCV infection and treatment commencement, median (IQR) | 36 (30–46) | 34 (27–52) | 37 (30–46) |
| HCV treatment | |||
| PEG ± RBV | 103 (86) | 8 (80) | 95 (86) |
| PEG-IFN + RBV + telaprevir | 10 (8) | 1 (10) | 9 (8) |
| Sofosbuvir + RBV | 7 (6) | 1 (10) | 6 (5) |
| Treatment weeks, median (IQR) | 24 (16–24) | 20 (8–24) | 24 (16–24) |
| Time at risk of reinfection (years), median (IQR) | 1.08 (0.59, 1.50) | 0.67 (0.35, 1.23) | 1.19 (0.60, 1.52) |
a
Includes participants with ETR and no reinfection or relapse
Abbreviations: Injecting drug use (IDU); opiate substitution therapy (OST); pegylated interferon (PEG-IFN); ribavirin (RBV)